The Anti-inflammatory Effect of LXA4 in Local Tissues

HU Quandong^1,2, YANG Yujuan¹, YU Shanshan^1,3, FU Yuemei⁴

(¹Shaoxing Vocational & Technical College, Shaoxing 312000, China; ²Department of Pathophysiology, Institute of Basic Medical Science of Nanchang University, Nanchang 330006, China; ³Institute of Genetics and Developmental Biology, University of Chinese Academy of Sciences, Beijing 100101, China; ⁴Affiliated Hospital of Shaoxing University of Arts and Sciences, Shaoxing 312000, China)

Abstract:

LXA4 (lipoxin A4), an emerging endogenous arachidonic acid, is metabolized by the lipoxygenase pathway to form an effective anti-inflammatory substance that promotes the regression of inflammation and acts as a endogenous “brake signal” during inflammatory process. It promotes the treatment of obesity and related diseases by promoting the regression of inflammation of white adipose tissue. Fixing LXA4 on the biological agent and delivering it to the treatment site can promote local inflammation dissipation and periodontal damage repair. As a receptor agonist of LXA4, BML-111 also has a pro-inflammatory remission effect. This article briefly reviews the anti-inflammatory mechanism of LXA4 and its receptor agonists in local tissues.

CSTR: 32200.14.cjcb.2019.12.0022